[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

@NEJM Avatar @NEJM NEJM

NEJM posts on X about events, treat, rates, red the most. They currently have XXXXXXX followers and XX posts still getting attention that total XXXXXX engagements in the last XX hours.

Engagements: XXXXXX #

Engagements Line Chart

Mentions: XX #

Mentions Line Chart

Followers: XXXXXXX #

Followers Line Chart

CreatorRank: XXXXXXX #

CreatorRank Line Chart

Social Influence

Social category influence finance XXXX% countries XXXX%

Social topic influence events #2092, treat 2.63%, rates 2.63%, red 2.63%, education 2.63%, express 2.63%, insurance 2.63%, united states 2.63%, history 2.63%, level XXXX%

Top accounts mentioned or mentioned by @ashhematology @erictopol @doc_blocke @vfd_org @drrishabhonco @bllphd @patientstormdoc @asnkidney @nufeinbergmed @uabnews @dglaucomflecken @umasschan @uwmedicine @cidrap @svinsociety @catharinazkh @veraghali @suhas_gondi @dr_amerzeidan @matthewshaw1111

Top Social Posts

Top posts by engagements in the last XX hours

"Presented at #ASH25: In a new study gene editing with a prime editor was used to treat two persons with chronic granulomatous disease caused by a small deletion in the gene NCF1. Full study results: @ASH_hematology"
X Link 2025-12-07T13:05Z 933.2K followers, 32K engagements

"Presented at #ASH25: Among men with hemophilia B sustained endogenous factor IX expression and low annualized bleeding rates over the course of X years were seen after an infusion of etranacogene dezaparvovec. Full HOPE-B phase X trial results: @ASH_hematology"
X Link 2025-12-07T17:06Z 933.2K followers, 12.7K engagements

"Treatments are needed for C3 glomerulopathy and primary immune-complex membranoproliferative glomerulonephritis. Pegcetacoplan a targeted C3 and C3b inhibitor showed promise in phase X trials. Research findings from the VALIANT phase X trial are summarized in a new Quick Take video"
X Link 2025-12-07T20:00Z 933.2K followers, 14.6K engagements

"Presented at #ASH25: In relapsed or refractory T-cell acute lymphoblastic leukemia off-the-shelf allogeneic base-edited CAR7 T cells mediated responses in XX patients enabling stem-cell transplantation in X patients in deep remission. Full study results: @ASH_hematology"
X Link 2025-12-08T21:35Z 933.2K followers, 38.8K engagements

"Which one of the following choices is the enzyme that is deficient in patients with Pompe disease"
X Link 2025-12-09T20:16Z 933.2K followers, 8485 engagements

"Presented at #KidneyWk: In the PISCES trial involving participants receiving hemodialysis fish oil (n3 fatty acids) was compared with corn-oil placebo. The rate of serious cardiovascular events was lower with daily fish-oil supplementation. Full trial results: Editorial: Fish Oil for Patients Receiving Hemodialysis Red Herring or Great Catch @ASNKidney"
X Link 2025-11-07T16:35Z 933.2K followers, 192.6K engagements

"Bedside clinical skills have been diminished by an overreliance on technology. A new Review Article presents educational strategies for reinvigorating the bedside encounter and shows how much can be learned from it. Read the review Strategies to Reinvigorate the Bedside Clinical Encounter the latest in the Medical Education series by Brian T. Garibaldi MD MEHP and Stephen W. Russell MD from @NUFeinbergMed and the University of Alabama at Birmingham (@UABNews):"
X Link 2025-11-15T22:00Z 933.2K followers, 95.3K engagements

"Twelve former commissioners of the FDA express concern that the agencys recent moves will undermine a regulatory model designed to ensure vaccine safety effectiveness and availability. Read the full Perspective:"
X Link 2025-12-03T22:10Z 933.2K followers, 32.8K engagements

"A new trial of pegcetacoplan a C3 and C3b inhibitor in patients with C3 glomerulopathy or primary immune-complex membranoproliferative glomerulonephritis showed that the drug significantly reduced proteinuria. Full VALIANT phase X trial results and Research Summary:"
X Link 2025-12-10T14:00Z 933.2K followers, 8979 engagements

"Perspective by Stacie B. Dusetzina PhD and Rachel E. Sachs JD MPH: Insurance Coverage and Pricing of Weight-Loss Drugs in the United States #HealthPolicy #PublicHealth"
X Link 2025-12-11T22:00Z 933.2K followers, 8320 engagements

"New in the November XX 2025 issue of NEJM: Early Discontinuation of Aspirin after PCI (TARGET-FIRST trial) Early Withdrawal of Aspirin after PCI (NEO-MINDSET trial) Daily Mosnodenvir as Dengue Prophylaxis CRISPR-Cas9 Targeting ANGPTL3 Engasertib in Hereditary Hemorrhagic Telangiectasia Subscribe to NEJM for the latest medical research:"
X Link 2025-11-27T14:00Z 933.2K followers, 17.9K engagements

"Original Article: Early Withdrawal of Aspirin after PCI in Acute Coronary Syndromes (NEO-MINDSET trial) Editorial: Discontinuation of Aspirin in Acute Coronary Syndromes Treated with Coronary-Artery Stents #Cardiology"
X Link 2025-11-30T14:00Z 933.3K followers, 45.5K engagements

"Idiopathic normal-pressure hydrocephalus (iNPH) typically causes gait cognitive and urinary impairment. The diagnosis is aided by a medical evaluation imaging findings and tests that predict improvement with CSF shunting. Learn more in the Review Article Idiopathic Normal-Pressure Hydrocephalus by Mark D. Johnson MD PhD and Michael A. Williams MD from @UMassChan and @UWMedicine:"
X Link 2025-12-03T22:40Z 933.2K followers, 47.6K engagements

"New in the December X 2025 issue of NEJM: Glucocorticoids for Community-Acquired Pneumonia (SONIA trial) Shunting for Idiopathic Normal-Pressure Hydrocephalus (PENS trial) Pegcetacoplan in C3 Glomerulopathy and IC-MPGN (VALIANT phase X trial) Subscribe to NEJM for the latest medical research:"
X Link 2025-12-04T14:00Z 933.2K followers, 35.5K engagements

"Brief Report: Prime Editing for p47-Deficient Chronic Granulomatous Disease #ASH25 @ASH_hematology"
X Link 2025-12-08T12:58Z 933.3K followers, 14.7K engagements

"Presented at #ASH25: In the VAYHIT2 phase X trial ianalumab plus eltrombopag led to a longer time to treatment failure than placebo plus eltrombopag with a stable platelet response at X months in a higher percentage of patients with X mg/kg of ianalumab than with placebo. Full trial results: @ASH_hematology"
X Link 2025-12-09T12:35Z 933.3K followers, 13.1K engagements

"Presented at #SVIN25: CREST-2: In high-grade asymptomatic carotid stenosis addition of stenting to medical therapy led to a lower risk of stroke over a 4-year period. Endarterectomy did not lead to a significant benefit. Full results: Editorial: Managing Asymptomatic Carotid Stenosis @svinsociety"
X Link 2025-11-21T15:35Z 933.2K followers, 383.1K engagements

"Presented at #ASH25: In untreated chronic lymphocytic leukemia fixed-duration venetoclax-based regimens were noninferior to continuous ibrutinib with regard to 3-year progression-free survival and were associated with higher MRD-negative rates. Full CLL17 phase X trial results: @ASH_hematology"
X Link 2025-12-06T13:35Z 933.2K followers, 19.7K engagements

"Original Article: Fixed-Duration versus Continuous Treatment for Chronic Lymphocytic Leukemia (CLL17 phase X trial) #ASH25 @ASH_hematology"
X Link 2025-12-07T14:04Z 933.2K followers, 32.8K engagements

"In patients with idiopathic normal-pressure hydrocephalus responsive to CSF drainage shunting improved gait and balance at X months but not cognition or incontinence and was associated with some procedure-related risks. Full PENS trial results and Research Summary:"
X Link 2025-12-09T14:00Z 933.2K followers, 17.9K engagements

"An 80-year-old man presented to the emergency department with a 12-hour history of pleuritic chest pain and an elevated d-dimer level. A CT scan showed an ulcerlike projection in the ascending thoracic aorta. Read the full case details in the Images in Clinical Medicine article Aortic Intramural Hematoma from Catharina Hospital (@CatharinaZKH):"
X Link 2025-12-10T23:00Z 933.2K followers, 11.9K engagements

"A trial of pegcetacoplan a C3 and C3b inhibitor in patients with C3 glomerulopathy or primary immune-complex membranoproliferative glomerulonephritis showed that the drug significantly reduced proteinuria. Full VALIANT phase X trial results: Editorial: Pegcetacoplan for Treatment of C3 Glomerulopathy and Immune-Complex MPGN"
X Link 2025-12-03T22:30Z 933.2K followers, 13.7K engagements

"Presented at #ASH25: In drug-resistant extramedullary myeloma dual treatment with talquetamab and teclistamab produced a response in XX% of patients and 12-month overall survival was 74%; however grade X or X adverse events were common. Full RedirecTT-1 phase 1b2 study results: @ASH_hematology"
X Link 2025-12-07T21:35Z 933.2K followers, 24.7K engagements

"In X of XX patients receiving immune checkpoint inhibitors cell-free DNA methylation profiling revealed multiorgan damage with immune-related adverse events often before symptoms appeared. Learn more:"
X Link 2025-12-10T22:30Z 933.2K followers, 46.3K engagements

"Original Article: High-Dose Influenza Vaccine Effectiveness against Hospitalization in Older Adults (DANFLU-2 trial) Editorial: Current and Emerging Approaches to Evaluating Influenza Vaccine Performance #IDTwitter"
X Link 2025-12-12T20:00Z 933.2K followers, 13.6K engagements